Acebutolol hydrochloride - CAS 34381-68-5
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acebutolol hydrochloride
Catalog Number:
34381-68-5
Synonyms:
Acebutolol hydrochloride
CAS Number:
34381-68-5
Description:
Acebutolol is a β-adrenergic receptors antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.
Molecular Weight:
372.89
Molecular Formula:
C18H28N2O4.HCl  
COA:
Inquire
MSDS:
Inquire
Targets:
Adrenergic Receptor
Chemical Structure
CAS 34381-68-5 Acebutolol hydrochloride

Related Adrenergic Receptor Products


CP-331684
(CAS: 207922-70-1)

CP-331684 is a β3-adrenergic receptor agonist used as antidiabetic drug.

CAS 51322-75-9 Tizanidine

Tizanidine
(CAS: 51322-75-9)

Tizanidine, a short-acting drug, is an agonist at a2-adrenergic receptor reducing spasticity by increasing presynaptic inhibition of motor neurons.

Etiguanfacine
(CAS: 1346686-31-4)

Etiguanfacine is a α2-Adreno Receptor agonist using for the treatment of ADHD (Attention deficit hyperactivity disorder).

Tedatioxetine
(CAS: 508233-95-2)

Tedatioxetine is an antidepressant agent. It acts as a triple reuptake inhibitor and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist. It was discov...

CAS 847829-38-3 Rezatomidine

Rezatomidine
(CAS: 847829-38-3)

Rezatomidine is a selective α2-adrenoreceptor antagonist under the development of Allergan. No recent development was reported for the treatment of Diabetic neu...

CAS 6452-71-7 Oxprenolol

Oxprenolol
(CAS: 6452-71-7)

Oxprenolol is a lipophilic, non-selective beta-adrenergic blocker. It has some intrinsic sympathomimetic activity and is used for the treatment of angina pector...

CAS 770-05-8 DL-Octopamine hydrochloride

DL-Octopamine hydrochloride
(CAS: 770-05-8)

Octopamine hydrochloride is an α-adrenoceptor agonist.

SNAP-8719 HCl
(CAS: 255893-38-0)

SNAP-8719, structurally very similar to BMY-7378, is a selective, orally active α1D-AR antagonist with lower binding affinity for the 5-HT1A receptor.

CAS 144481-98-1 Landiolol hydrochloride

Landiolol hydrochloride
(CAS: 144481-98-1)

Landiolol is an ultra-short-acting Beta 1 adrenergic receptor antagonist using for managing supraventricular tachyarrhythmias in sepsis. It is also used as an a...

BMS-194449
(CAS: 170686-12-1)

BMS-194449 was found to be a β-adrenergic receptor agonist that was once studied in antihyperglycaemics as well as obesity therapy.

Vilanterol trifenatate
(CAS: 503070-58-4)

Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Br...

CAS 58020-43-2 Hoku-81

Hoku-81
(CAS: 58020-43-2)

Hoku 81 is a bronchodilator, and one of the metabolites of tulobuterol.

MK-467
(CAS: 130466-38-5)

MK-467 is a peripheral Alpha2 -adrenoceptor antagonist originated by Merck & Co. It can dose-dependently attenuate the bradycardia associated with dexmedetomidi...

CAS 4205-91-8 Clonidine Hydrochloride

Clonidine Hydrochloride
(CAS: 4205-91-8)

Clonidine HCl is a direct-acting α2 adrenergic agonist with an ED50 of 0.02±0.01 mg/kg.

CAS 22195-34-2 Guanadrel Hemisulfate

Guanadrel Hemisulfate
(CAS: 22195-34-2)

Guanadrel, as an antihypertensive agent, is an orally active postganglionic sympathetic inhibitor.

Nolomirole hydrochloride
(CAS: 138531-51-8)

Nolomirole is a Alpha 2 adrenergic receptor and Dopamine D2 receptor agonist. Nolomirole can attenuate the heart failure signs in the monocrotaline-induced cong...

CAS 59803-98-4 Brimonidine

Brimonidine
(CAS: 59803-98-4)

Brimonidine is α2-Adrenoceptor agonist. It is a drug used as eye drops to treat open-angle glaucoma or ocular hypertension. It acts via decreasing synthesis of ...

CAS 106463-17-6 Tamsulosin HCl

Tamsulosin HCl
(CAS: 106463-17-6)

The hydrochloride salt form of Tamsulosin which could block on the sympathetic α1 receptor, especially selectively bind to the α1A receptor so that has been fou...

CAS 57149-07-2 Naftopidil

Naftopidil
(CAS: 57149-07-2)

Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM.

CAS 65576-45-6 Asenapine

Asenapine
(CAS: 65576-45-6)

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug by combining serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related ...

Reference Reading


1.First Case Report of Smith-Magenis Syndrome (SMS) Among the Arab Community in Nazareth: View and Overview.
Nijim Y1, Adawi A, Bisharat B, Bowirrat A. Medicine (Baltimore). 2016 Jan;95(3):e2362. doi: 10.1097/MD.0000000000002362.
Smith-Magenis syndrome (SMS0) is a complex and rare genetic multisystem disorder characterized by a variable pattern of cognitive deficits accompanied by a1 distinctive behavioral phenotype. SMS is characterized by subtle facial dysmorphology, short stature, sleep disturbances, and neurobehavioral abnormalities. Little is known about the manifestation of his unique case among Arab population and its strategic treatment.This study comes to present a case of SMS in an Arab newborn male who was born in spontaneous delivery on June 29, 2015, with tachypnea, tracheomalacia, and mild hypotonia. The newborn was admitted on the Neonatal Intensive Care Unit (NICU), and various laboratory examinations and clinical examinations were performed.Throughout his hospitalization, feeding difficulties appeared and thus a peripheral venous catheter was inserted in the left leg.After 22 days of follow-up and hospitalizations, the patient status improved and he was discharged with recommendations to be in follow up in pediatric outpatient clinic.
2.Aqueous chlorination of acebutolol: kinetics, transformation by-products, and mechanism.
Khalit WN1, Tay KS2. Environ Sci Pollut Res Int. 2016 Feb;23(3):2521-9. doi: 10.1007/s11356-015-5470-y. Epub 2015 Oct 1.
This study investigated the reaction kinetics and the transformation by-products of acebutolol during aqueous chlorination. Acebutolol is one of the commonly used β-blockers for the treatment of cardiovascular diseases. It has been frequently detected in the aquatic environment. In the kinetics study, the second-order rate constant for the reaction between acebutolol and chlorine (k app) was determined at 25 ± 0.1 °C. The degradation of acebutolol by free available chlorine was highly pH dependence. When the pH increased from 6 to 8, it was found that the k app for the reaction between acebutolol and free available chlorine was increased from 1.68 to 11.2 M(-1) min(-1). By comparing with the reported k app values, the reactivity of acebutolol toward free available chlorine was found to be higher than atenolol and metoprolol but lower than nadolol and propranolol. Characterization of the transformation by-products formed during the chlorination of acebutolol was carried out using liquid chromatography-quadrupole time-of-flight high-resolution mass spectrometry.
3.Development of SPME-LC-MS method for screening of eight beta-blockers and bronchodilators in plasma and urine samples.
Goryński K1, Kiedrowicz A2, Bojko B3. J Pharm Biomed Anal. 2016 Mar 4. pii: S0731-7085(16)30119-4. doi: 10.1016/j.jpba.2016.03.001. [Epub ahead of print]
The current work describes the development and validation of a simple, efficient, and fast method using solid phase microextraction coupled to liquid chromatography-tandem mass spectrometry (SPME-LC-MS/MS) for the concomitant measurement of eight beta-blockers and bronchodilators in plasma and urine. The presented assay enables quantitative determination of acebutolol, atenolol, fenoterol, nadolol, pindolol, procaterol, sotalol, and timolol. In this work, samples were prepared on a high-throughput platform using the 96-well plate format of the thin film solid phase microextraction (TFME) system, and a biocompatible extraction phase made of hydrophilic-lipophilic balance particles. Analytes were separated on a pentafluorophenyl column (100mm×2.1mm, 3μm) by gradient elution using an UPLC Nexera coupled with an LCMS-8060 mass spectrometer. The mobile phase consisted of water-acetonitrile (0.1% formic acid) at a flow rate of 0.4mLmin-1. The linearity of the method was checked within therapeutic blood-plasma concentrations, and shown to adequately reflect typically expected concentrations of future study samples.
4.Upregulation of P-glycoprotein expression by ophthalmic drugs in different corneal in-vitro models.
Verstraelen J1, Reichl S. J Pharm Pharmacol. 2015 May;67(5):605-15. doi: 10.1111/jphp.12357. Epub 2015 Jan 23.
OBJECTIVES: The purpose of this study was to analyse P-glycoprotein (P-gp) expression in different human in-vitro cornea models (HCE-T epithelial model and Hemicornea construct) after stimulation with P-gp substrates (rhodamine 123, levofloxacin and acebutolol).